Skip to main content
Health Updated October 2026

Strategic HTA and Market Access in the Pharmaceutical Industry

8 and 9 January 2027 | Online

Last updated: October 2026

Course Description

Purpose and rationale

A molecule that clears its regulator has cleared roughly half the distance to a patient. The remaining half is decided by agencies that ask different questions of the same evidence, by reference pricing baskets that propagate one badly chosen launch price across a continent, and by budget holders whose constraint is cash in the current year rather than efficiency over a lifetime. This course is built for the people who work that second half.

It is a workshop rather than a lecture series. Across two days, participants complete nineteen applied exercises, each one a decision a market access team actually faces: how much a delay costs, which PICO survives a hundred-day window, how to rescue an ICER that lands fifty per cent above threshold, which market to launch in first, and what to say when a payer opens with the objection everyone knew was coming. Each exercise follows the same rhythm (Challenge, Do, Check) and no exercise is left with an unverified answer.

By the close of Day 2 each participant holds two artefacts: a completed workbook of seven quantitative models, and a twelve-document written file ending in a three-objection payer playbook assembled from their own earlier work.

Who should attend

  • Market access, pricing and reimbursement professionals in pharmaceutical and biotechnology companies.
  • HEOR and health economics staff who build or defend submissions to HTA agencies.
  • Medical affairs and clinical development staff whose trial design decisions determine what a payer can later be shown.
  • Commercial and launch planning teams responsible for launch sequencing and price corridor management.
  • Regulatory affairs professionals who need to understand where regulatory sufficiency and payer sufficiency diverge.
  • Consultants and agency staff supporting HTA submissions, value dossiers and payer negotiations.


What You'll Learn

Quantify the commercial cost of access delay across markets and build a defensible access-timeline model with a launch Gantt view.
Construct a three-pillar value dossier (clinical, economic, humanistic) that names the gap a payer will see in each pillar and the concrete mitigation that closes it.
Translate a single global label into jurisdiction-specific PICOs, and prioritise them against the evidentiary and time constraints of an EU Joint Clinical Assessment.
Design real-world evidence and indirect-comparison strategies that survive HTA scrutiny, and justify the method selected to a named agency.
Build ICER, budget impact and one-way sensitivity models in a spreadsheet using formulas throughout, and interpret the result against a stated threshold.
Rescue an over-threshold ICER using legitimate commercial and analytical levers, and state the trade-off each lever carries.
Sequence market launches to protect the international price corridor, and draft enforceable managed-entry and outcome-based agreements.
Tailor payer-facing argumentation to the archetype in the room, and answer standard payer objections with a named mechanism and a named evidence artefact.